A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Guselkumab at 52 weeks for the Treatment of Psoriatic Arthritis

Main Article Content

Richard Warren
Iain McInnes
Peter Nash
Jean-Marie Grouin
Damon Willems
Vanessa Taieb
Jason Eells
Philip Mease

Keywords

psoriatic arthritis

References

Ritchlin CT et al. Ann Rheum Dis 2023;ard-2023-224431;

Merola JF et al. Lancet 2023;401(10370):38–48;

McInnes IB et al. Arthritis Rheumatol. 2021;73(4):604–616;

Coates LC et al. Ann Rheum Dis. 2022;81(3):359–369;

EMA. 2022;

Mease P et al. (ISPOR), Boston, USA, May 2023;

Signorovitch JE et al. Value Health 2012;15(6):940–947;

Philippo DM et al. Med Decis Making 2018;38(2):200–211

Most read articles by the same author(s)